Journal
CANCER RESEARCH AND TREATMENT
Volume 50, Issue 4, Pages 1462-1466Publisher
KOREAN CANCER ASSOCIATION
DOI: 10.4143/crt.2017.473
Keywords
Refractory/relapse; B-cell lymphoma; Chimeric antigen receptor T cells; Terminal ileal perforation
Categories
Funding
- 973 Program [2015-CB964900]
- Natural Science Foundation of China [81230014, 81470341, 81500157, 81770201, 81730008]
- Key Project of Science and Technology Department of Zhejiang Province [2015C03G2010091]
Ask authors/readers for more resources
Chimeric antigen receptor T-cell strategy targeting CD19 (CART19) has prominent anti-tumor effect for relapsed/refractory B-cell lymphomas. CART19-associated complications have been gradually recognized, however, late-onset complications have not been extensively studied. Herein, for the first time we report a diffuse large B-cell lymphoma patient with terminal ileum involvement obtained rapid remission and developed spontaneous terminal ileal perforation 38 days following CART19 infusion. The late-onset perforation reminds us that, for the safety of CART treatment, more cautions are warranted for the management of delayed GI complications.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available